Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A novel prostate cancer therapeutic strategy using icaritin-activated arylhydrocarbon-receptor to co-target androgen receptor and its splice variants

23 Apr 2015

Abstract excerpt

Persistent androgen receptor (AR) signaling is the key driving force behind progression and development of castration-resistant prostate cancer (CRPC). In many patients, AR COOH-terminal truncated splice variants (ARvs) play a critical role in contributing to the resistance against androgen depletion therapy. Unfortunately, clinically used antiandrogens like bicalutamide (BIC) and enzalutamide (MDV), which target...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Medicinal Plant Pharmacodynamics Research
Share to Prostate Cancer Treatment and Research
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25908644
DOI: 10.1093/carcin/bgv040

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A novel prostate cancer therapeutic strategy using icaritin-activated arylhydrocarbon-receptor to co-target androgen receptor and its splice variantsPMID 25908644Read ↗

Constitutive activity of the androgen receptor.Semantic proximity Read ↗

Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

Molecules targeting the androgen receptor (AR) signaling axis beyond the AR‐Ligand binding domainSemantic proximity Read ↗

A compendium of Androgen Receptor Variant 7 target genes and their role in Castration Resistant Prostate CancerSemantic proximity Read ↗

Steroidogenic Enzyme AKR1C3 Is a Novel Androgen Receptor-Selective Coactivator that Promotes Prostate Cancer GrowthSemantic proximity Read ↗

A Naturally Derived Small Molecule Disrupts Ligand-Dependent and Ligand-Independent Androgen Receptor Signaling in Human Prostate Cancer CellsSemantic proximity Read ↗

Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancerSemantic proximity Read ↗

Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancerSemantic proximity Read ↗

Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.Semantic proximity Read ↗

Targeting androgen receptor and the variants by an orally bioavailable Proteolysis Targeting Chimeras compound in castration resistant prostate cancerSemantic proximity Read ↗

Androgen receptor variants: RNA-based mechanisms and therapeutic targetsSemantic proximity Read ↗

Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.